Get the Stockscreener App
2.10
0.94%
-0.02
Spero Therapeutics Inc stock is traded at $2.10, with a volume of 480.92K.
It is down -0.94% in the last 24 hours and down -17.32% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.12
Open:
$2.12
24h Volume:
480.92K
Relative Volume:
0.50
Market Cap:
$121.59M
Revenue:
$54.77M
Net Income/Loss:
$15.24M
P/E Ratio:
8.6207
EPS:
0.2436
Net Cash Flow:
$7.24M
1W Performance:
-4.55%
1M Performance:
-17.32%
6M Performance:
-17.65%
1Y Performance:
-26.06%
1-Day Range:
$2.05
$2.1565
1-Week Range:
$2.05
$2.23
52-Week Range:
$1.80
$3.08
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.10 | 121.59M | 54.77M | 15.24M | 7.24M | 0.2436 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors - Yahoo! Finance Canada
Spero Therapeutics outlines its antibiotic pipeline as investors track regulatory progress - ad-hoc-news.de
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell 3000E Growth Benchmark - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell 3000E Index - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell Microcap Index - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Form 4 Spero Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
Spero Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPRO) - TradingView
Spero Therapeutics, Inc. Actuals & Estimates (BOATS:SPRO) - TradingView
Spero Therapeutics Expands Stock Incentive Plan and Authorization - The Globe and Mail
Spero Therapeutics (SPRO) director awarded RSUs and 20,000-share option - Stock Titan
Spero Therapeutics (SPRO) director receives RSU and stock option awards - Stock Titan
Spero Therapeutics (SPRO) director receives 10,000 RSUs and 20,000-share option grant - Stock Titan
Spero Therapeutics (SPRO) director awarded RSUs and stock options - Stock Titan
Spero Therapeutics (SPRO) grants director RSUs and 20,000 stock options - Stock Titan
Equity awards to Spero (NASDAQ: SPRO) director Scott Jackson - Stock Titan
Spero Therapeutics (SPRO) director receives RSU and 20,000-share option grant - Stock Titan
Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock plan - Stock Titan
SPRO Forecast — Price Target — Prediction for 2027 - TradingView
Spero Therapeutics (SPRO) Slips 3.81% as Selling Pressure Tests Key Support LevelsSystematic Flow - dars.gov.et
Spero Therapeutics Inc (SPRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
FDA clears Spero (NASDAQ: SPRO) oral Utebzi antibiotic for complicated UTIs - Stock Titan
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs - Yahoo Finance
Spero Therapeutics Inc (NASDAQ: SPRO) Share Price, SPRO Stock News, SPRO Share Price & Updates - Kalkine
US FDA approves GSK's oral antibiotic for drug-resistant UTIs - Reuters
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics Stock: Antibiotic Development In Focus - Kalkine Media
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections - TradingView
Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spero Therapeutics Inc (SPRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spero Therapeutics Inc (SPRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AlTi Global And 2 Other Promising Penny Stocks To Watch - simplywall.st
Spero Therapeutics and GSK Announce FDA Approval of Utebzi, the First Oral Carbapenem Antibiotic for Complicated Urinary Tract Infections in the US - Quiver Quantitative
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) - GlobeNewswire
FDA approves first oral carbapenem for complicated UTIs in adults - Stock Titan
GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections - Moomoo
GSK, Spero Therapeutics Gain U.S. Approval for Utebzi - marketscreener.com
SPRO Stock Slumps As Volatility Grips Small-Cap Biotech - timothysykes.com
Spero Therapeutics Approaches Key FDA Decision For Tebipenem HBr In CUTIs - RTTNews
Spero Therapeutics Inc (SPRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spero Therapeutics Inc (SPRO) Institutional Confidence - TradingKey
Spero Therapeutics Inc (SPRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spero Therapeutics Inc (SPRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Spero Therapeutics Inc (SPRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Spero Therapeutics Stock (US85208T1079): Quiet session keeps focus on fundamentals and pipeline - AD HOC NEWS
SPRO Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentSlow Growth Warning - dars.gov.et
SPRO News | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold) - Seeking Alpha
Spero Therapeutics Inc. Q1 2026 Earnings: Better-Than-Expected Loss Provides Little Respite as Shares FallMargin Guidance - dars.gov.et
Spero Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls Amid Lack of Revenue - newsline.com
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):